MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 319101 | Name: Zuclopenthixol
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Zuclopenthixol, also known as Cisordinol, Clopixol, Acuphase, zuclopentixol, is a typical antipsychotic drug of the thioxanthene class. It was introduced in 1962 by Lundbeck. Zuclopenthixol is the cis-isomer of clopenthixol. Zuclopenthixol is not approved for use in the United States. Zuclopenthixol has high affinity for both dopamine D1 and D2 receptors, for α1-adrenoceptors and 5-HT2 receptors but no affinity for cholinergic muscarine receptors. It has weak histamine (H1) receptor affinity and no α2-adrenoceptor blocking activity.

Chemical Structure

Zuclopenthixol
Zuclopenthixol
CAS#53772-83-1 (free base)

Theoretical Analysis

MedKoo Cat#: 319101

Name: Zuclopenthixol

CAS#: 53772-83-1 (free base)

Chemical Formula: C22H25ClN2OS

Exact Mass: 400.1376

Molecular Weight: 400.97

Elemental Analysis: C, 65.90; H, 6.28; Cl, 8.84; N, 6.99; O, 3.99; S, 8.00

Price and Availability

Size Price Availability Quantity
100mg USD 250.00 2 Weeks
200mg USD 450.00 2 Weeks
500mg USD 750.00 2 Weeks
1g USD 1,350.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
53772-83-1 (free base) 58045-23-1 (HCl) 85721-05-7 (acetate) 64053-00-5 (decanoate)
Synonym
alpha-Clopenthixol; Cisordinol; Clopenthixol; Zuclopenthixol; Cisordinol; cis-Clopenthixol; Clopixol;
IUPAC/Chemical Name
2-[4-[(3Z)-3-(2-chlorothioxanthen-9-ylidene)propyl]piperazin-1-yl]ethanol
InChi Key
WFPIAZLQTJBIFN-DVZOWYKESA-N
InChi Code
InChI=1S/C22H25ClN2OS/c23-17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)27-22)5-3-9-24-10-12-25(13-11-24)14-15-26/h1-2,4-8,16,26H,3,9-15H2/b18-5-
SMILES Code
ClC1=CC(/C2=C\CCN3CCN(CCO)CC3)=C(SC4=C2C=CC=C4)C=C1
Appearance
White to off-white solid powder.
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related CAS# 53772-83-1; 85721-05-7 (acetate); 64053-00-5 (decanoate).

Preparing Stock Solutions

The following data is based on the product molecular weight 400.97 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Solhaug V, Waade RB, Molden E, Størset E, Høiseth G, Tveito M. The Effect of Age on Antipsychotic Serum Concentration in Males and Females: A Study Based on Therapeutic Drug Monitoring Data From 19,926 Patients. Ther Drug Monit. 2025 Feb 25. doi: 10.1097/FTD.0000000000001309. Epub ahead of print. PMID: 39996570. 2: Storman D, Koperny M, Styczeñ K, Datka W, Jaeschke RR. Lurasidone versus typical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2025 Jan 20;1(1):CD012429. doi: 10.1002/14651858.CD012429.pub2. PMID: 39831535; PMCID: PMC11744762. 3: Tien Y, Huang HP, Chan CH, Huang SC, Wang VX. Addition of long-acting injectable antipsychotics during manic episodes in bipolar disorder: A retrospective analysis of rehospitalizations. J Affect Disord. 2025 Mar 15;373:325-332. doi: 10.1016/j.jad.2024.12.088. Epub 2025 Jan 3. PMID: 39756485. 4: O'Neill JR, Taylor DM, Horowitz MA. Using in silico methods to determine optimal tapering regimens for decanoate-based long-acting injectable psychosis drugs. Ther Adv Psychopharmacol. 2024 Sep 12;14:20451253241272790. doi: 10.1177/20451253241272790. PMID: 39282238; PMCID: PMC11401015. 5: Ragia G, Pallikarou M, Manolopoulou Y, Vorvolakos T, Manolopoulos VG. Genetic diversity of cytochrome P450 in patients receiving psychiatric care in Greece: a step towards clinical implementation. Pharmacogenomics. 2024;25(5-6):217-229. doi: 10.1080/14622416.2024.2346072. Epub 2024 May 14. PMID: 38884939; PMCID: PMC11388136. 6: Lin W, Xia Y, He A, Chen S, Zhang J. Antipsychotic Zuclopenthixol Inhibits Melanoma Growth and Brain Metastasis by Inducing Apoptosis and Cell Cycle Arrest. Front Biosci (Landmark Ed). 2024 Mar 29;29(4):132. doi: 10.31083/j.fbl2904132. PMID: 38682202. 7: Turan S, Ermiş Ç, Eray Ş, Ağaç N, Karakuş OB, Sağlam Y, Bandırma A, Güler D, Tunçtürk M, Çıray RO, Karaçetin G, İnal N, Üçok A. Illness-related outcomes of illicit substance use disorder in adolescents with early onset schizophrenia: a multicenter study. J Addict Dis. 2024 Apr 2:1-5. doi: 10.1080/10550887.2024.2332512. Epub ahead of print. PMID: 38566305. 8: Barros FMR, Tolentino AC, Marques LSK, Schlittler LXC, Oliveira KD, Dalgalarrondo P, Barnes LL, Dos Santos Junior A, Banzato CEM. Successful Clozapine Rechallenge After Clozapine-Induced Severe Anemia: A Case Report. Schizophr Bull. 2024 Apr 30;50(3):717-719. doi: 10.1093/schbul/sbae028. PMID: 38502910; PMCID: PMC11059803. 9: Jameson A, Faisal M, Fylan B, Bristow GC, Sohal J, Dalton C, Sagoo GS, Cardno AG, McLean SL. Proportion of Antipsychotics with CYP2D6 Pharmacogenetic (PGx) Associations Prescribed in an Early Intervention in Psychosis (EIP) Cohort: A Cross-Sectional Study. J Psychopharmacol. 2024 Apr;38(4):382-394. doi: 10.1177/02698811241238283. Epub 2024 Mar 17. PMID: 38494658; PMCID: PMC11010551. 10: Kumar S U, Varghese RP, Preethi VA, Doss CGP, Zayed H. Identification of Potential Inhibitors Targeting GTPase-Kirsten RAt Sarcoma Virus (K-Ras) Driven Cancers via E-Pharmacophore-Based Virtual Screening and Drug Repurposing Approach. Front Biosci (Landmark Ed). 2023 Nov 14;28(11):288. doi: 10.31083/j.fbl2811288. PMID: 38062837. 11: Rillon P, Zdanowicz N, Jacques D, Dubois T. A Case of Central Venous Sinus Thrombosis after Injection of Zuclopenthixol. Psychiatr Danub. 2023 Oct;35(Suppl 2):417-418. PMID: 37800268. 12: Kenar ANI, Unal GA, Mert A, Ay AM. Potential benefits of combining two long- acting injectable antipsychotic: a retrospective study. Eur Rev Med Pharmacol Sci. 2023 Sep;27(18):8609-8613. doi: 10.26355/eurrev_202309_33785. PMID: 37782176. 13: Mansour E, Danaf S, Ghousayneh D, Assaf G, Ghantous I, El-Khoury F. Zuclopenthixol Induced Ischemic Priapism: Case Report and Review of Literature. J Family Reprod Health. 2023 Jun;17(2):109-112. doi: 10.18502/jfrh.v17i2.12875. PMID: 37547784; PMCID: PMC10397527. 14: Lähteenvuo M, Paljärvi T, Tanskanen A, Taipale H, Tiihonen J. Real-world effectiveness of pharmacological treatments for bipolar disorder: register-based national cohort study. Br J Psychiatry. 2023 Oct;223(4):456-464. doi: 10.1192/bjp.2023.75. PMID: 37395140; PMCID: PMC10866673. 15: Miroshnichenko II, Baymeeva NV, Platova AI, Kaleda VG. Terapevticheskii lekarstvennyi monitoring antipsikhoticheskikh preparatov v povsednevnoi psikhiatricheskoi praktike [Therapeutic drug monitoring of antipsychotic drugs in routine psychiatric practice]. Zh Nevrol Psikhiatr Im S S Korsakova. 2023;123(5):145-152. Russian. doi: 10.17116/jnevro2023123051145. PMID: 37315254. 16: Beunk L, Nijenhuis M, Soree B, de Boer-Veger NJ, Buunk AM, Guchelaar HJ, Houwink EJF, Risselada A, Rongen GAPJM, van Schaik RHN, Swen JJ, Touw D, van Westrhenen R, Deneer VHM, van der Weide J. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics. Eur J Hum Genet. 2024 Mar;32(3):278-285. doi: 10.1038/s41431-023-01347-3. Epub 2023 Mar 31. PMID: 37002327; PMCID: PMC10923774. 17: Sardari E, Ebadi A, Razzaghi-Asl N. In silico repurposing of CNS drugs for multiple sclerosis. Mult Scler Relat Disord. 2023 May;73:104622. doi: 10.1016/j.msard.2023.104622. Epub 2023 Mar 16. PMID: 36958175. 18: Larsen JB, Hoffmann-Lücke E, Aaslo PH, Jørgensen NR, Greibe E. Automated Interlaboratory Comparison of Therapeutic Drug Monitoring Data and Its Use for Evaluation of Published Therapeutic Reference Ranges. Pharmaceutics. 2023 Feb 16;15(2):673. doi: 10.3390/pharmaceutics15020673. PMID: 36839995; PMCID: PMC9964937. 19: Auxilia AM, Buoli M, Caldiroli A, Carnevali GS, Tringali A, Nava R, Clerici M, Capuzzi E. High Rate of Discontinuation during Long-Acting Injectable Antipsychotic Treatment in Patients with Psychotic Disorders. Biomedicines. 2023 Jan 22;11(2):314. doi: 10.3390/biomedicines11020314. PMID: 36830850; PMCID: PMC9953565. 20: Vellar K, Khalid U, Coleman M. Quality improvement through audit: Zuclopenthixol acetate prescribing, monitoring and patient outcomes in a regional health service. Australas Psychiatry. 2023 Feb;31(1):27-33. doi: 10.1177/10398562231154311. PMID: 36772936.

View History

C.I. 13900

C.I. 13900